With interest we read the article by Dos Santos et al. about a retrospective, multicenter study on the effect and safety of rituximab (RTX) in patients >18y with myasthenia gravis (MG) in 6 centers of Western France [1]. It was concluded that RTX is effective and safe for MG [1]. We have the following comments and concerns.

中文翻译：

---

有必要对利妥昔单抗治疗重症肌无力的疗效进行前瞻性研究。

我们感兴趣地阅读了Dos Santos等人的文章。关于法国西部6个中心的18岁以上重症肌无力（MG）患者中利妥昔单抗（RTX）疗效和安全性的回顾性多中心研究[1]。结论是RTX对MG有效且安全[1]。我们有以下评论和关注。